Clinical-stage biopharmaceutical company CymaBay Therapeutics will lose its CMO Pol Boudes, MD, who is leaving the company on his own accord.
What you should know:
1. Dr. Boudes will resign Sept. 30.
2. CymaBay began searching for his replacement.
3. Gideon Hirschfield, MD, will provide medical and clinical support while the company searches for a fulltime replacement.
4. CymaBay is developing treatments for liver and other chronic diseases.